Equities Analysts Decrease Earnings Estimates for Oxford BioMedica plc (OTCMKTS:OXBDF)

Equities Analysts Decrease Earnings Estimates for Oxford BioMedica plc (OTCMKTS:OXBDF)

Oxford BioMedica plc (OTCMKTS:OXBDF) – Equities research analysts at Jefferies Financial Group cut their FY2019 EPS estimates for shares of Oxford BioMedica in a research note issued to investors on Thursday, January 9th, Zacks Investment Research reports. Jefferies Financial Group analyst P. Gardner now forecasts that the company will earn ($0.32) per share for the year, down from their prior estimate of ($0.30). Jefferies Financial Group also issued estimates for Oxford BioMedica’s FY2020 earnings at ($0.09) EPS, FY2021 earnings at ($0.37) EPS, FY2022 earnings at ($0.27) EPS and FY2023 earnings at ($0.18) EPS.

Several other research firms also recently commented on OXBDF. HC Wainwright reaffirmed a “buy” rating on shares of Oxford BioMedica in a report on Thursday, December 19th. ValuEngine upgraded shares of Oxford BioMedica from a “hold” rating to a “buy” rating in a research note on Tuesday. Finally, Zacks Investment Research downgraded Oxford BioMedica from a “buy” rating to a “hold” rating in a research report on Tuesday, January 14th.

Shares of Oxford BioMedica stock traded down $0.43 on Monday, reaching $8.22. 108 shares of the stock were exchanged, compared to its average volume of 1,463. Oxford BioMedica has a twelve month low of $6.20 and a twelve month high of $10.02. The firm has a market capitalization of $539.89 million, a price-to-earnings ratio of 54.80 and a beta of 0.80. The business has a 50 day moving average price of $8.51 and a two-hundred day moving average price of $7.79.

About Oxford BioMedica

Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson’s, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.

Share:
Scroll Up
error: Content is protected !!